Since the outbreak of the COVID-19 virus, AGBL has been working with suppliers and partner labs to test and validate products for the clinical diagnosis of the COVID-19 virus. This has resulted in AGBL’s ability to offer comprehensive solutions in the diagnosis and follow-up of such cases across the emerging markets.
Such solutions comprise of ultra sensitive PCR kits that comply with WHO and European Union IVD regulations. In addition, AGBL offers manual extraction kits as well as automated extraction platforms for the RNA of the virus. For the High Throughput Labs, AGBL offers lab automation solutions to cope with high throughput testing for the virus.
An example of the innovative solutions offered by AGBL through one of its partners, Avicenna, is Avilab ™, a bench-top mobile lab testing solution.
Over the past month, AGBL has supplied over 200,000 testing kits, as well as supported governments throughout the region in their fight against COVID-19, including Tunisia, Lebanon, Morocco, KSA, Ethiopia, Ghana, Pakistan and many more, through the supply of highly sensitive detection solutions. AGBL has also partnered with many private and public labs to assist them in the early diagnosis of positive cases.
For more information on our activity within COVID-19, please click here for The News section.
To enquire about any of our products, kindly fill out the form below.
AGBL Afrique has announced that its customer Center of Biotechnology of Sfax (CBS) has successfully completed its first full SARS-CoV2 sequencing in Tunisia. The sequencing of the virus was performed at the CBS in collaboration [...]